The safety and pharmacodynamic results in the multiple-dose trial must be interpreted in light of the high dose levels (2040 mg oral semaglutide) and the relatively fast initial dose escalation in this trial compared with the phase III trials, where dose levels of 314 mg oral semaglutide are investigated and a slower initial dose escalation is used to minimise gastrointestinal adverse effects
Drugs Today (Barc) 2005;41(7):453-9
Tsiskarishvili T, Katsitadze A, Tsiskarishvili NV, Mgebrishvili E, Tsiskarishvili NI
There are currently no generic versions of semaglutide medications, including Ozempic and Wegovy
Certain individuals should refrain from semaglutide, particularly those with personal or familial medullary thyroid cancer history, or multiple endocrine neoplasia type 2
This injectable medication helps individuals with type 2 diabetes manage their blood sugar levels